Cargando…

Amplification of mutant KRAS(G12D) in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancer types. Activating oncogenic KRAS mutations are commonly observed in PDAC; however, oncogenic KRAS amplification is rarely observed, and its significance in prognosis and resistance to therapy remains poorly characterized. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pittella-Silva, Fabio, Kimura, Yasutoshi, Low, Siew-Kee, Nakamura, Yusuke, Motoya, Masayo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278405/ https://www.ncbi.nlm.nih.gov/pubmed/34276991 http://dx.doi.org/10.3892/mco.2021.2334

Ejemplares similares

Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
por: Nagayama, Satoshi, et al.
Publicado: (2021)

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)

Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer
por: Watanabe, Kazunori, et al.
Publicado: (2022)

Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
por: Chan, Hiu Ting, et al.
Publicado: (2020)

KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
por: Chiari, Rita, et al.
Publicado: (2023)

Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy
por: Chan, Hiu Ting, et al.
Publicado: (2020)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas
por: Rehkaemper, Jan, et al.
Publicado: (2020)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas
por: Sumi, Toshiyuki, et al.
Publicado: (2018)

Transcolonic endoscopic ultrasound-guided fine-needle biopsy to diagnose a pancreatic tail adenocarcinoma in a patient with surgically altered anatomy
por: Kawakami, Yujiro, et al.
Publicado: (2022)

Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma
por: Zhao, Huan, et al.
Publicado: (2017)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

KRAS-specific antibody binds to KRAS protein inside colorectal adenocarcinoma cells and inhibits its localization to the plasma membrane
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Liquid biopsy in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy
por: Matsusaka, Satoshi, et al.
Publicado: (2016)

Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas
por: Li, Jinyu, et al.
Publicado: (2016)

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma
por: Nakamura, Toru, et al.
Publicado: (2022)

PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis
por: Essakly, Ahlem, et al.
Publicado: (2019)

BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma
por: Alden, Stephanie L., et al.
Publicado: (2020)

Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
por: Buscail, Etienne, et al.
Publicado: (2019)

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing
por: Holm, Matilda, et al.
Publicado: (2020)

Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
por: Liu, Ke, et al.
Publicado: (2018)

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia
por: Saliakoura, Maria, et al.
Publicado: (2020)

Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
por: Best, Sarah A., et al.
Publicado: (2019)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
por: Liu, Liang, et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

The Metastatic Cascade as the Basis for Liquid Biopsy Development
por: Eslami-S, Zahra, et al.
Publicado: (2020)

Arteriovenous malformation in pancreas mimicking hypervascular tumor
por: Ishigami, Keisuke, et al.
Publicado: (2020)

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
por: Naseem, Madiha, et al.
Publicado: (2021)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016)

Opa1 and Drp1 reciprocally regulate cristae morphology, ETC function, and NAD(+) regeneration in KRas-mutant lung adenocarcinoma
por: Sessions, Dane T., et al.
Publicado: (2022)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report
por: Boby, Jeffrey Mathew, et al.
Publicado: (2022)

Metastatic Melanoma: Liquid Biopsy as a New Precision Medicine Approach
por: Ricciardi, Elena, et al.
Publicado: (2023)

A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS
por: Zhang, Xiang-Hua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qk90r32kfcrv20c2mhuankm0mc